---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-24-000034"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:33:46.482976+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xencor Regains Exclusive Worldwide Rights to Plamotamab After Janssen Termination

## Summary
- Xencor regains worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen terminates its rights.
- Plamotamab is Phase 2 ready, having completed Phase 1 enrollment in hematologic cancers in late 2023.
- Janssen retains rights to develop B-cell targeting CD28 bispecifics, including JNJ-9401 and JNJ-1493, now in Phase 1.
- Two collaboration agreements with Janssen continue; Xencor remains eligible for milestones and royalties on retained CD28 programs.
- Xencor has opt-in rights to co-fund development of JNJ-9401 (20%) and JNJ-1493 (15%) upon proof-of-concept.

## SEC filing metadata
- accession: 0001326732-24-000034
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000034/0001326732-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000034/xncr-20240613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-24-000034
- JSON: https://secwatch.observer/filing/0001326732-24-000034.json
- Plain text: https://secwatch.observer/filing/0001326732-24-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.